Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avalo Therapeutics Inc

15.35
+1.359.64%
Post-market: 15.31-0.0400-0.26%18:33 EDT
Volume:364.31K
Turnover:5.35M
Market Cap:201.89M
PE:-2.56
High:15.49
Open:13.93
Low:13.60
Close:14.00
52wk High:16.00
52wk Low:3.39
Shares:13.15M
Float Shares:12.46M
Volume Ratio:1.62
T/O Rate:2.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0077
EPS(LYR):-7.9367
ROE:-90.25%
ROA:-32.01%
PB:1.93
PE(LYR):-1.93

Loading ...

Company Profile

Company Name:
Avalo Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
23
Office Location:
540 Gaither Road,Suite 400,Rockville,Maryland,United States
Zip Code:
20850
Fax:
- -
Introduction:
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Directors

Name
Position
Garry Neil
Director,President and Chief Executive Officer
Michael Heffernan
Chairman of the Board
Aaron Kantoff
Director
Gilla Kaplan
Director
Jonathan Goldman
Director
Kevin Lind
Director
Mitchell Chan
Director
Rita Jain
Director
Samantha Truex
Director

Shareholders

Name
Position
Garry Neil
Director,President and Chief Executive Officer
Christopher Sullivan
Chief Financial Officer
Jennifer Riley
Chief Strategy Officer
Mittie Doyle
Chief Medical Officer
Paul Varki
Chief Legal Officer
Taylor Boyd
Chief Business Officer